SMMDB: a web-accessible database for small molecule modulators and their targets involved in neurological diseases

Abstract High-throughput screening and better understanding of small molecule’s structure–activity relationship (SAR) using computational biology techniques have greatly expanded the face of drug discovery process in better discovery of therapeutics for various disease. Small Molecule Modulators Database (SMMDB) includes >1100 small molecules that have been either approved by US Food and Drug Administration, are under investigation or were rejected in clinical trial for any kind of neurological diseases. The comprehensive information about small molecules includes the details about their molecular targets (such as protein or enzyme, DNA, RNA, antisense RNA etc.), pharmacokinetic and pharmacodynamic properties such as binding affinity to their targets (Kd, Ki, IC50 and EC50 if available), mode of action, log P-value, number of hydrogen bond donor and acceptors, their clinical trial status, their 2D and three-dimensional structures etc. To enrich the basic annotation of every small molecule entry present in SMMDB, it is hyperlinked to their description present in PubChem, DrugBank, PubMed and KEGG database. The annotation about their molecular targets was enriched by linking it with UniProt and GenBank and STRING database that can be utilized to study the interaction and relation between various targets involved in single neurological disease. All molecules present in the SMMDB are made available to download in single file and can be further used in establishing the SAR, structure-based drug designing as well as shape-based virtual screening for developing the novel therapeutics against neurological diseases. The scope of this database majorly covers the interest of scientific community and researchers who are engaged in putting their endeavor toward therapeutic development and investigating the pathogenic mechanism of various neurological diseases. The graphical user interface of the SMMDB is accessible on http://bsbe.iiti.ac.in/bsbe/smmdb.

[1]  Venkateswara Rao Talluri,et al.  Shape based virtual screening and molecular docking towards designing novel pancreatic lipase inhibitors , 2015, Bioinformation.

[2]  Alex J. Smith,et al.  The aquaporin-4 water channel as a potential drug target in neurological disorders , 2017, Expert opinion on therapeutic targets.

[3]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[4]  I. Bertini,et al.  SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization , 2008, PloS one.

[5]  K. Anthony,et al.  Aberrant RNA processing events in neurological disorders , 2010, Brain Research.

[6]  Christopher R Fetsch,et al.  Effects of Cortical Microstimulation on Confidence in a Perceptual Decision , 2014, Neuron.

[7]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[8]  S. Hadano,et al.  A novel function of N-linked glycoproteins, alpha-2-HS-glycoprotein and hemopexin: Implications for small molecule compound-mediated neuroprotection , 2017, PloS one.

[9]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[10]  S. F. Cappa,et al.  Motor neuron dysfunctions in the frontotemporal lobar degeneration spectrum: A clinical and neurophysiological study , 2015, Journal of the Neurological Sciences.

[11]  Adriano Chiò,et al.  State of play in amyotrophic lateral sclerosis genetics , 2013, Nature Neuroscience.

[12]  R. Franco,et al.  Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[13]  Matthew D Disney,et al.  A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. , 2012, ACS chemical biology.

[14]  Francisco Ciruela,et al.  GABAB receptors-associated proteins: potential drug targets in neurological disorders? , 2012, Current drug targets.

[15]  L. J. Eldik,et al.  Targeting protein kinases in central nervous system disorders , 2009, Nature Reviews Drug Discovery.

[16]  P. Spano,et al.  Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases. , 2018, Handbook of experimental pharmacology.

[17]  J. Issa,et al.  Targeting DNA Methylation , 2009, Clinical Cancer Research.

[18]  Li-Huei Tsai,et al.  MicroRNAs in learning, memory, and neurological diseases. , 2012, Learning & memory.

[19]  J. Kirchmair,et al.  Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..

[20]  Steven P. Gygi,et al.  An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons , 2017, The Journal of Biological Chemistry.

[21]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[22]  P. Jin,et al.  Understanding the molecular basis of fragile X syndrome. , 2000, Human molecular genetics.

[23]  B. Trapp,et al.  Multiple sclerosis: an immune or neurodegenerative disorder? , 2008, Annual review of neuroscience.

[24]  Peter Ertl,et al.  JSME: a free molecule editor in JavaScript , 2013, Journal of Cheminformatics.

[25]  A. White,et al.  Neurocysticercosis: a major cause of neurological disease worldwide. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[27]  David Borsook,et al.  Neurological diseases and pain. , 2012, Brain : a journal of neurology.

[28]  M. Mehler,et al.  Understanding neurological disease mechanisms in the era of epigenetics. , 2013, JAMA neurology.

[29]  Ankita Mehta,et al.  SMMRNA: a database of small molecule modulators of RNA , 2013, Nucleic Acids Res..

[30]  Viachaslau Bernat,et al.  RNA Structures as Mediators of Neurological Diseases and as Drug Targets , 2015, Neuron.

[31]  Daniel L. Alkon,et al.  Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials , 2017, Journal of Alzheimer's disease : JAD.

[32]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[33]  K. Subba Rao.  Mechanisms of disease: DNA repair defects and neurological disease. , 2007, Nature clinical practice. Neurology.

[34]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[35]  Jason E Gestwicki,et al.  Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo , 2012, Autophagy.

[36]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[37]  Frederik Barkhof,et al.  The role of spinal cord imaging in the diagnosis of multiple sclerosis , 2006, Nature Clinical Practice Neurology.

[38]  Philip E. Bourne,et al.  Will a Biological Database Be Different from a Biological Journal? , 2005, PLoS Comput. Biol..

[39]  Christian Lüscher,et al.  The synapse: center stage for many brain diseases , 2009, The Journal of physiology.

[40]  Matthew D Disney,et al.  Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. , 2012, ACS chemical biology.

[41]  W D Wilson,et al.  Targeting RNA with small molecules. , 2000, Current medicinal chemistry.

[42]  J. Cleary,et al.  Repeat-associated non-ATG (RAN) translation in neurological disease , 2013, Human molecular genetics.

[43]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[44]  R. Franco,et al.  Phosphodiesterases as therapeutic targets for Alzheimer's disease. , 2012, ACS chemical neuroscience.

[45]  A. Waszkielewicz,et al.  Send Orders of Reprints at Reprints@benthamscience.net Ion Channels as Drug Targets in Central Nervous System Disorders , 2022 .

[46]  Christopher A Lipinski,et al.  Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. , 2016, Advanced drug delivery reviews.

[47]  Monica Soto-Velasquez,et al.  Identification of FDA-Approved Small Molecules Capable of Disrupting the Calmodulin-Adenylyl Cyclase 8 Interaction through Direct Binding to Calmodulin. , 2017, ACS chemical neuroscience.

[48]  C. Chuaqui,et al.  Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI) , 2003 .

[49]  Ashfaq Ul Hassan,et al.  Role of stem cells in treatment of neurological disorder. , 2009, International journal of health sciences.